课题基金 / 基金详情

BLOOD PROGENITOR CELL MOBILIZATION BY R-METHUSCF & R-METHUG-CSF IN BREAST CANCER

BLOOD PROGENITOR CELL MOBILIZATION BY R-METHUSCF & R-METHUG-CSF IN BREAST CANCER
R-METHUSCF 动员血液祖细胞
批准号：
6244976
负责人：
Thomas C. Shea
金额：
$1.34万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-01-06 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6244976
关键词：
CD34 molecule antineoplastics breast neoplasms clinical research clinical trials colony stimulating factor combination cancer therapy dosage hematopoietic growth factor human subject human therapy evaluation intracellular transport metastasis neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy neutrophil platelets recombinant proteins

项目摘要

项目成果

Thomas C. Shea的其他基金

相似基金

相关文献

中文摘要
翻译
为了比较收获至少5 x 10-6所需的蜂群数量 CD34+细胞/公斤实际体重，使用r-metHUSCF 联合Filgra-stim或Filgrastin单独用于动员或 高危期II、III期患者的祖细胞 四期乳腺癌。证明等同的嫁接，如 通过中性粒细胞和血小板的恢复来评估，PBPC由 R-metHUSCF加FilgrasTim或单独用作Filgratim时 大剂量化疗后的细胞支持。
英文摘要
To compare the number of aphereses required to harvest at least 5 x 10-6 CD34+ cells/kg actual body weight, using either r-metHUSCF in combination with Filgra-stim or Filigrastim alone for mobilization or progenitor cells in patients with high risk Stage II, Stage III or Stage IV breast cancer. To demonstrate equivalent engraftment, as assessed by recovery of neutophils and platelets, PBPC mobilized by either r-metHUSCF plus Filigrastim or Filgrastim alone when used as cellular support post high dose chemotherapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM
FILGRASTIM ALONE OR IN COMBINATION W/ R METHUSCF IN BREAST CANCER
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS
PHARMACODYNAMIC MODELING OF ORAL ETOPOSIDE IN RELAPSED NON HODGKINS
海外基金